; (ii) in paragraph (2)(A), in the matter preceding clause (i), by striking and (9) and inserting , (9), and (10) ; and (iii) by adding at the end the following new paragraph: (10) Limitations on cost-sharing for opioid overdose reversal agents (A) In general For plan year 2025 and each subsequent plan year, each prescription drug plan and MA–PD plan shall not impose any cost-sharing requirement under the plan with respect to at least one brand or generic version of an opioid overdose reversal agent (as defined in section 2799A–11 of the Public Health Service Act). The requirement under the preceding sentence shall also apply to cost-sharing applicable to subsidy eligible individuals under section 1814D–14. (B) Cost-sharing For purposes of subparagraph (A), the elimination of cost-sharing shall include the following: (i) No application of deductible The waiver of the deductible under paragraph (1). (ii) No application of coinsurance The waiver of coinsurance under paragraph (2). ; and (B) in subsection (c), by adding at the end the following new paragraph: (7) Treatment of cost-sharing for opioid overdose reversal agents The coverage is provided in accordance with subsection (b)(10). . (2) Conforming amendments to cost-sharing for low-income individuals Section 1860D–14(a) of the Social Security Act ( 42 U.S.C. 1395w–114(a) ) is amended— (A) in paragraph (1), in the matter preceding subparagraph (A), by striking In the case and inserting Subject to section 1860D–2(b)(10), in the case